Best in Biotech 19 Dec 2023
Nine biotech companies to watch in 2024
2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024.
- Latest Posts
Opinion 18 Dec 2023
What to expect from biotech clinical trials in the coming year
As cancer research has seen an increase in funding lately, here are some of the key clinical trends that you can expect in 2024.
Weekly Roundup 15 Dec 2023
Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
Podcast 15 Dec 2023
Vaxxinity making vaccines to change the world
Discover how Vaxxinity’s vaccine approach aims to democratize global health, potentially reshaping access to innovative treatments worldwide.
Best in Biotech 14 Dec 2023
Seven companies shaping the future of precision medicine
Explore the forefront of healthcare innovation with these seven cutting-edge biopharma companies specializing in precision medicine.
In Depth 13 Dec 2023
Revolutionizing glioblastoma treatment: how CAR-T cell therapy could be used as a cure
Find out how CAR-T cell therapy, which has been so groundbreaking in treating blood cancers, could be used to cure glioblastoma.
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 12 Dec 2023
Five biotech companies based in Dubai you should know about
The Middle East’s industry is rapidly growing, with several key players emerging in the region. Notably, Qatar, Saudi Arabia, and the United Arab Emirates (UAE) are at the forefront of this expansion. Our focus today zeros in on the UAE, particularly Dubai and its biotech companies, renowned for being one of the most strategic and […]
In Depth 11 Dec 2023
European patents in biotech: how to prevent invalid patents?
The ongoing patent battle between COVID-19 vaccine giants, Pfizer-BioNTech and Moderna, has seen a new development when the European Patent Office (EPO) invalidated one of Moderna’s patents related to “respiratory virus vaccines.” BioNTech, in collaboration with Pfizer and Sanofi, opposed the patent, leading to its invalidation. The European patent process is complex but essential. As […]
Weekly Roundup 8 Dec 2023
Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
Podcast 8 Dec 2023
Can worms provide treatments for some diseases?
U.S. company Holoclara is looking to tackle diseases through the development of worm-derived therapeutics. Allergic and autoimmune diseases were first described in the early 1900s, which Holoclara said is the same time that gut-resident worms such as the roundworm, Caenorhabditis elegans, were removed from people in industrialized countries. The company, led by CEO Andrea Choe, […]
News and Trends 7 Dec 2023
BIO-Europe 2023: top ten highlights
The biopharma community met at Munich in Germany for BIO-Europe 2023, where attendees from across the world took part in networking events to foster collaboration, last month. With a turnout of nearly 6000 participants and more than 150 exhibitors, the event hosted a number of panel discussions. In collaboration with our parent company, life science […]
In Depth 7 Dec 2023
The biggest private biotech investments in November 2023
The companies Cambrian Innovation, Terremoto Biosciences, and VectorY Therapeutics bagged the biggest biotech investments in November 2023. Around the world, oncology and central nervous system players attracted the biggest funding rounds. As we edge closer to Christmas, biotech fundraising appears to be drying up a bit; there was a significant decrease in funding rounds in […]
ADVERTISEMENT
